ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 185 filers reported holding ASCENDIS PHARMA A/S in Q3 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $315,000 | -35.7% | 3,391 | -18.8% | 0.14% | -59.1% |
| Q1 2022 | $490,000 | +2.3% | 4,178 | +17.4% | 0.35% | -61.7% |
| Q4 2021 | $479,000 | -12.9% | 3,560 | +3.2% | 0.91% | +24.5% |
| Q3 2021 | $550,000 | +17.0% | 3,451 | -5.3% | 0.73% | +58.9% |
| Q1 2021 | $470,000 | +3.8% | 3,646 | +34.2% | 0.46% | -4.3% |
| Q4 2020 | $453,000 | -46.5% | 2,717 | -50.5% | 0.48% | +9.3% |
| Q3 2020 | $847,000 | +34.0% | 5,486 | +28.3% | 0.44% | +4.5% |
| Q2 2020 | $632,000 | +62.5% | 4,276 | +23.7% | 0.42% | +44.4% |
| Q1 2020 | $389,000 | -47.8% | 3,458 | -35.4% | 0.29% | -28.9% |
| Q4 2019 | $745,000 | +66.3% | 5,357 | +37.7% | 0.41% | +34.2% |
| Q2 2019 | $448,000 | – | 3,891 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |